- Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
- Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
- Cellectis publie ses résultats financiers du premier trimestre 2022
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
- Monthly information on share capital and company voting rights
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Cellectis annonce ses résultats financiers pour le premier trimestre 2022
- Cellectis to Report First Quarter 2022 Financial Results
- Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
- Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
More ▼
Key statistics
As of last trade, Cellectis SA (0WA2:LSE) traded at 3.30, 18.92% above the 52 week low of 2.78 set on May 13, 2022.
52-week range
Markit short selling activity
Open | 3.32 |
---|---|
High | -- |
Low | -- |
Bid | 3.25 |
Offer | 3.42 |
Previous close | 3.30 |
Average volume | 40.72k |
---|---|
Shares outstanding | 45.48m |
Free float | 38.34m |
P/E (TTM) | -- |
Market cap | 134.83m EUR |
EPS (TTM) | -2.85 EUR |
Data delayed at least 20 minutes, as of May 17 2022 18:00 BST.
More ▼